{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-043101","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.365832+00:00","generated_at":"2026-06-14T14:30:06.336309+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Relmada Therapeutics stockholders approve plan amendment and elect directors","bullets":["Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 2,500,000 to 7,900,000.","Charles J. Casamento and Sergio Traversa elected as Class II directors with 10,159,479 and 17,003,403 votes respectively.","Ratification of Marcum LLP as independent auditor for fiscal 2023 approved with 22,048,083 votes.","Approximately 76.9% of eligible common stock voted at the annual meeting held on May 25, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-043101","json":"https://secwatch.observer/filing/0001213900-23-043101.json","markdown":"https://secwatch.observer/filing/0001213900-23-043101.md","text":"https://secwatch.observer/filing/0001213900-23-043101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/0001213900-23-043101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/ea179287-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:30:06.336309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72779b4ce4fad3237c26bef27bc560c35951ac19","claim":"RELMADA THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Auditors at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/0001213900-23-043101-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"86fc907f8cd3703d9257bf9a56996db09e535979","claim":"RELMADA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2026 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/0001213900-23-043101-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"edbf972eeb2b3e5e05392eca727f8db5b855fa4d","claim":"RELMADA THERAPEUTICS, INC. shareholders approved Approval of an amendment to the 2021 Plan at the 2023-05-25 meeting.","evidence_excerpt":"Proposal 3: Approval of an amendment to the 2021 Plan. Stockholders approved the amendment to the Company’s 2021 Plan described in","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023043101/0001213900-23-043101-index.htm","confidence":0.4,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}